N,N'-bis(3-aminopropyl)propane-1,3-diamine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Remarks:

i.p.

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

3 (not reliable)

Rationale for reliability incl. deficiencies:

unsuitable test system

Remarks:

unphysiological route of application

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1970

Report date:

1970

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

BASF-Test. 5 mice per sex and dose were simultaneously treated intraperitoneally. Group-wise documentation of clinical signs was performed over a 14 day study period. The clinical signs and findings were reported in summary form. On the basis of the observed lethality, the LD50 value was estimated or determined using a graphical evaluation of the dose response curve on probability paper.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

N,N'-bis(3-aminopropyl)propane-1,3-diamine

EC Number:

225-007-8

EC Name:

N,N'-bis(3-aminopropyl)propane-1,3-diamine

Cas Number:

4605-14-5

Molecular formula:

C9H24N4

IUPAC Name:

N,N'-bis(3-aminopropyl)propane-1,3-diamine

Test animals

Species:

mouse

Strain:

other: Kisslegg

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: young adults
- Weight at study initiation: 24 - 39 g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Remarks:

aqueous emulsion with Traganth

Details on exposure:

VEHICLE
- Concentration in vehicle: 20%, 10%, 8%, 4%, 2% aqueous emulsion with Traganth

Doses:

20, 32, 40, 50, 100, 200,1600 mm3/kg bw (corresponding to 18.4, 29.4, 36.8, 46, 92, 184, 1472 mg/kg bw; calculated using the density of 0.92 g/cm³)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations: several times on the day of application and daily thereafter
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Key result

Sex:

male/female

Dose descriptor:

LC50

Effect level:

32.2 mg/kg bw

Based on:

test mat.

Mortality:

1472 mg/kg: 5/5 m ; 5/5 w
184 mg/kg 4/5 m; 5/5 w
92 mg/kg 5/5 m, 5/5 w
46 mg/kg 5/5 m, 5/5 w
36.8 mg/kg 3/5 m ; 5/5 w
29.4 mg/kg 0/5 m; 4/5 w
18.4 mg/kg 0/0 m; 0/5 w

Clinical signs:

1472 mg/kg:Immediately after application, the animals showed accelerated or shock-like breathing and complete apathy. After 2 hours the animals died.
184 mg/kg : Immediately after application, the animals showed accelerated or shock-like breathing and complete apath and with a tumbling. After 2 hours nine animals died.The last animal had a rough coat and accelerated breathing the next day. He died within the 14-day follow-up.
92 mg/kg (18.4, 29.4, 36.8, 46 mg/kg) Immediately after application, the animals showed accelerated or shock-like breathing, trembling and twitching. Delayed movements of the extremities. Half-closed or completely closed eyes, folded ears, collapsed flanks and restless behavior. Subsequent observation showed them crouching there, showing accelerated breathing and rough fur and glued eyes. The animals died on day 7 or 14 post application. Only at the lowest dosage did no animal die.

Body weight:

no data